<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-30-12-2025-shutterstock_2383470841-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-30-12-2025-shutterstock_2383470841-430x241.jpg"/></p>
<p>强生预计 2025 年第四季度及 2026 年将出现收益稀释。图片来源：Skorzewiak/Shutterstock.com。</p>
<p>强生（J&amp;J）已完成对 Halda Therapeutics 的收购，这是一家临床阶段的生物技术公司，收购金额为 30.5 亿美元现金。</p>
<p>此举将 Halda 的调控诱导邻近靶向嵌合体（RIPTAC）平台纳入强生的肿瘤学产品组合，支持针对包括前列腺癌在内的多种实体肿瘤的口服靶向疗法的开发。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - JNJ-6358 在肺腺癌中的应用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM：4D Pharma Plc 的 MRx-518</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>此次收购包括 HLD-0915，这是一种临床阶段的每日一次口服前列腺癌疗法。该疗法利用 RIPTAC 平台精确靶向癌细胞，旨在解决耐药机制。</p>
<p>此外，该交易还为强生的产品管线增加了早期阶段的乳腺癌、肺癌及其他肿瘤类型的候选药物，均采用 RIPTAC 技术。</p>
<p>公司表示，该平台可能使得开发肿瘤学以外的其他靶向疗法成为可能。</p>
<p>随着交易在 2025 年完成，强生预计 2025 年第四季度及 2026 年将出现收益稀释。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>来自 GlobalData</p>
<p>了解更多关于战略情报</p>
<p>对调整后每股收益的总影响预计约为 0.20 美元，平均分配在 2025 年和 2026 年，反映与 Halda 员工股权、融资和整合成本相关的费用。</p>
<p>强生创新药物全球主席兼执行副总裁 Jennifer Taubert 表示：“这一战略里程碑强调了我们通过突破性科学和变革性药物重新定义癌症治疗的承诺。</p>
<p>“我们很高兴正式欢迎才华横溢的 Halda 团队加入强生，并期待共同努力实现消除癌症的共同目标。”</p>
<p>强生创新药物研发执行副总裁 John Reed 表示：“现在我们已完成此次收购，我们将专注于推进这一有前景的创新产品候选药物管线的潜力，并利用强大的 RIPTAC 平台发现更多肿瘤学及其他领域的分子。”</p>
<p>2025 年 11 月，强生 签署了最终协议 收购 Halda。</p>
<h2>制药技术卓越奖 - 提名已关闭</h2>
<p>提名现已关闭，感谢所有参与的组织——你们的响应非常出色，展示了卓越的创新、领导力和影响力。</p>
<p><strong>行动中的卓越</strong></p>
<p>因在 综合制造 方面的业务扩展而获得 2025 年制药技术卓越奖的 Upperton Pharma Solutions 正在迅速扩大其在英国的 GMP 和无菌制造足迹。了解 Upperton 的综合 CDMO 模型如何帮助制药公司从早期开发转向临床和小众商业供应，减少交接和加快时间表。</p>
<p>发现影响</p>

强生

<p>强生（Johnson & Johnson，J&J）以 30.5 亿美元现金收购 Halda Therapeutics，增强其肿瘤学产品组合，特别是 Halda 的调控诱导接近靶向嵌合体（RIPTAC）平台。此次收购包括 HLD-0915，一种用于前列腺癌的口服疗法，以及其他肿瘤的早期候选药物。J&J 预计由于整合成本，2025 年和 2026 年的每股收益将稀释约 0.20 美元。J&J 的高管强调此次收购在推进癌症治疗和开发新疗法方面的战略重要性</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-30-12-2025-shutterstock_2383470841-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-30-12-2025-shutterstock_2383470841-430x241.jpg"/></p>
<p>J&amp;J anticipates earnings dilution in the fourth quarter of 2025 and into 2026. Credit: Skorzewiak/Shutterstock.com.</p>
<div class="lb-trans"><p>强生预计 2025 年第四季度及 2026 年将出现收益稀释。图片来源：Skorzewiak/Shutterstock.com。</p>
</div><p>Johnson &amp; Johnson (J&amp;J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash.</p>
<div class="lb-trans"><p>强生（J&amp;J）已完成对 Halda Therapeutics 的收购，这是一家临床阶段的生物技术公司，收购金额为 30.5 亿美元现金。</p>
</div><p>This move brings Halda’s Regulated Induced Proximity Targeting Chimera (RIPTAC) platform to J&amp;J’s oncology portfolio, supporting the development of oral, targeted therapies for several solid tumours, including prostate cancer.</p>
<div class="lb-trans"><p>此举将 Halda 的调控诱导邻近靶向嵌合体（RIPTAC）平台纳入强生的肿瘤学产品组合，支持针对包括前列腺癌在内的多种实体肿瘤的口服靶向疗法的开发。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - JNJ-6358 in Lung Adenocarcinoma</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - JNJ-6358 在肺腺癌中的应用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: 4D Pharma Plc's MRx-518</h4>
<div class="lb-trans"><h4>NPVM：4D Pharma Plc 的 MRx-518</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>The acquisition includes HLD-0915, a clinical-stage, once-daily oral therapy for prostate cancer. This therapy utilises the RIPTAC platform for precision targeting of cancer cells, aiming to address resistance mechanisms.</p>
<div class="lb-trans"><p>此次收购包括 HLD-0915，这是一种临床阶段的每日一次口服前列腺癌疗法。该疗法利用 RIPTAC 平台精确靶向癌细胞，旨在解决耐药机制。</p>
</div><p>Additionally, the deal adds early-stage candidates for breast, lung, and other tumour types, using RIPTAC technology, to J&amp;J’s pipeline.</p>
<div class="lb-trans"><p>此外，该交易还为强生的产品管线增加了早期阶段的乳腺癌、肺癌及其他肿瘤类型的候选药物，均采用 RIPTAC 技术。</p>
</div><p>The company indicated that this platform could potentially enable the development of additional targeted therapies beyond oncology.</p>
<div class="lb-trans"><p>公司表示，该平台可能使得开发肿瘤学以外的其他靶向疗法成为可能。</p>
</div><p>With the deal closing in 2025, J&amp;J anticipates earnings dilution in the fourth quarter of 2025 and into 2026.</p>
<div class="lb-trans"><p>随着交易在 2025 年完成，强生预计 2025 年第四季度及 2026 年将出现收益稀释。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>来自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>The total impact on adjusted earnings per share is expected to be around $0.20, divided equally between 2025 and 2026, reflecting charges related to Halda employee equity, financing, and integration costs.</p>
<div class="lb-trans"><p>对调整后每股收益的总影响预计约为 0.20 美元，平均分配在 2025 年和 2026 年，反映与 Halda 员工股权、融资和整合成本相关的费用。</p>
</div><p>J&amp;J innovative medicine worldwide chairman and executive vice president Jennifer Taubert said: “This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines.</p>
<div class="lb-trans"><p>强生创新药物全球主席兼执行副总裁 Jennifer Taubert 表示：“这一战略里程碑强调了我们通过突破性科学和变革性药物重新定义癌症治疗的承诺。</p>
</div><p>“We are excited to formally welcome the talented Halda team to J&amp;J and look forward to working together to achieve our shared goal of eliminating cancer.”</p>
<div class="lb-trans"><p>“我们很高兴正式欢迎才华横溢的 Halda 团队加入强生，并期待共同努力实现消除癌症的共同目标。”</p>
</div><p>J&amp;J innovative medicine R&amp;D executive vice-president John Reed said: “Now that we have finalised this acquisition, we will focus on advancing the potential of this promising pipeline of novel product candidates and harnessing the powerful RIPTAC platform to discover more molecules in oncology and beyond.”</p>
<div class="lb-trans"><p>强生创新药物研发执行副总裁 John Reed 表示：“现在我们已完成此次收购，我们将专注于推进这一有前景的创新产品候选药物管线的潜力，并利用强大的 RIPTAC 平台发现更多肿瘤学及其他领域的分子。”</p>
</div><p>In November 2025, J&amp;J signed a definitive agreement for the acquisition of Halda.</p>
<div class="lb-trans"><p>2025 年 11 月，强生 签署了最终协议 收购 Halda。</p>
</div><h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
<div class="lb-trans"><h2>制药技术卓越奖 - 提名已关闭</h2>
</div><p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.</p>
<div class="lb-trans"><p>提名现已关闭，感谢所有参与的组织——你们的响应非常出色，展示了卓越的创新、领导力和影响力。</p>
</div><p><strong>Excellence in Action</strong></p>
<div class="lb-trans"><p><strong>行动中的卓越</strong></p>
</div><p>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
<div class="lb-trans"><p>因在 综合制造 方面的业务扩展而获得 2025 年制药技术卓越奖的 Upperton Pharma Solutions 正在迅速扩大其在英国的 GMP 和无菌制造足迹。了解 Upperton 的综合 CDMO 模型如何帮助制药公司从早期开发转向临床和小众商业供应，减少交接和加快时间表。</p>
</div><p>Discover the Impact</p>
<div class="lb-trans"><p>发现影响</p>
</div>

强生以 30.5 亿美元收购 Halda Therapeutics